West Nile Virus Infections Pipeline Therapeutics Development Review H2 2015

Press Release   •   Jan 12, 2016 09:16 EST

This report provides comprehensive information on the therapeutic development for West Nile Virus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for West Nile Virus Infections and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “West Nile Virus Infections” addition with 21 market data tables and 14 figures, spread across 56 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

BioDiem Ltd, CalAsia Pharmaceuticals, Inc., CEL-SCI Corporation, Kineta, Inc. and Nanotherapeutics, Inc.

Drugs Profile Discussed in this Research:

BG-323, CEL-1000, ETX-112, FDX-000, HydroVax-001, Innate Immune Adjuvants, Monoclonal Antibody for West Nile Virus Infections, RL-14C, RL-15A, rOAS, Small Molecule to Agonize IRF-3 for Viral Infections, Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection, Small Molecule to Inhibit NS3 Protease for Dengue and West Nile Virus Infections, Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections, Small Molecules to Inhibit Serine Protease for Viral Infections, Synthetic Peptide for West Nile Virus and Dengue Virus Infections, west nile virus vaccine, west nile virus vaccine and West Nile virus vaccine

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)


  • The report provides a snapshot of the global therapeutic landscape of West Nile Virus Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for West Nile Virus Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the West Nile Virus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the West Nile Virus Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for West Nile Virus Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding West Nile Virus Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Infectious Diseases Therapeutics Market. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries